Navigating international laboratory procurement for specialized synthetic peptides requires strict analytical verification and clear vendor transparency. For research institutions investigating growth hormone dynamics, securing high-purity CJC-1295 DAC online-verkäufe ensures reliable experimental reproducibility across cellular and animal models. PX1 Research provides USA-manufactured, HPLC-verified GHRH analogs tailored exclusively for in vitro and preclinical research applications.
Navigating international laboratory procurement for specialized synthetic peptides requires strict analytical verification and clear vendor transparency. For research institutions investigating growth hormone dynamics, securing high-purity CJC-1295 DAC online-verkäufe ensures reliable experimental reproducibility across cellular and animal models. PX1 Research provides USA-manufactured, HPLC-verified GHRH analogs tailored exclusively for in vitro and preclinical research applications.
CJC-1295 DAC online-verkäufe refer to international laboratory procurement channels for CJC-1295 with Drug Affinity Complex, a modified 30-amino acid growth hormone-releasing hormone (GHRH) analog. Designed for preclinical research, it forms a covalent bond with serum albumin, dramatically extending half-life to sustain growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion in experimental tissue repair models.
When sourcing research compounds through commercial channels, principal investigators must differentiate between consumer suppliers and verified laboratory vendors. Standard procurement protocols mandate that every lot of CJC-1295 DAC be accompanied by independent analytical documentation verifying chemical identity, sequence integrity, peptide purity, and heavy metal/endotoxin thresholds.
CJC-1295 DAC is a synthetic analog of human growth hormone-releasing hormone (GHRH), modified at specific amino acid residues to resist enzymatic cleavage. GHRH naturally binds to the GHRH receptor (GHRHR) on pituitary somatotropes, triggering a signal transduction cascade that stimulates the synthesis and pulsatile release of endogenous growth hormone. However, native GHRH (1-29) possesses a brief biological half-life in vivo—typically under 12 minutes—due to rapid degradation by circulating dipeptidyl peptidase IV (DPP-IV).
To counter rapid enzymatic degradation, researchers engineered CJC-1295 with amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) paired with a reactive bioconjugate linker. In preclinical literature, this peptide functions as a long-acting GHRH agonist, sustaining elevated plasma concentrations of GH and downstream IGF-1 over extended durations. Investigating these signaling pathways yields valuable data regarding somatotropic receptor regulation, cellular proliferation, and metabolic signaling in tissue repair models. For a broader overview of GHRH peptide kinetics, explore our resource on GHRH analogs overview.
The defining feature of CJC-1295 DAC is the incorporation of the Drug Affinity Complex (DAC) moiety—specifically, a maleimidopropionic acid (MPA) group attached via a lysine linker at the C-terminus. This functional group selectively reacts with free thiols, forming a stable covalent bond with circulating endogenous albumin (specifically Cys34 of serum albumin) upon administration in animal models.
By binding to serum albumin, the molecular mass of the peptide complex increases significantly, protecting the active GHRH peptide sequence from renal filtration and cleavage by DPP-IV. Preclinical rodent and non-human primate studies demonstrate that this bioconjugation extends the functional half-life of CJC-1295 DAC to approximately 6 to 8 days, compared to the 30-minute half-life observed with non-DAC variants. This extended kinetic profile allows researchers to maintain steady baseline stimulation of somatotropic axis activity without requiring frequent administration protocols in animal subjects.
When procuring specialized reagents via international digital storefronts (frequently searched as CJC-1295 DAC online-verkäufe), research facilities face significant variance in product quality, purity, and manufacturing standards. Unregulated suppliers often fail to provide complete lot-specific analytical data, increasing the risk of experimental contamination from synthesis side-products, residual trifluoroacetic acid (TFA), or bacterial endotoxins.
To safeguard research integrity, laboratory buyers should evaluate vendors against rigorous supply-chain criteria:
1. USA-Based Manufacturing: Peptides synthesized within ISO 17025-accredited and GMP-compliant domestic facilities adhere to strict quality control protocols during liquid-phase or solid-phase peptide synthesis (SPPS).
2. Lot-Specific Analytical Verification: Every batch must include an independent Certificate of Analysis (COA) containing raw high-performance liquid chromatography (HPLC) chromatograms and mass spectrometry (MS) spectra.
3. Quantitative Endotoxin Testing: Raw materials must undergo Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels fall below strict research thresholds (typically < 0.01 EU/µg).
4. Transparent Batch Traceability: Suppliers must maintain strict lot tracking from synthesis through lyophilization and distribution to ensure batch-to-batch consistency. Researchers can review all comprehensive product offerings in our main catalog of all peptides.
Definitive analytical validation relies on two primary orthogonal techniques: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). RP-HPLC separates the target CJC-1295 DAC molecule from truncated peptide sequences, deletion peptides, and residual organic solvents. A purity threshold of ≥98% peak area integration ensures that off-target signaling does not skew in vitro cellular assays or in vivo metabolic measurements.
Mass spectrometry confirms the exact molecular weight and structural identity of the synthesized compound, verifying the presence of both the modified GHRH sequence and the functional DAC linker. Furthermore, because bacterial endotoxins (lipopolysaccharides) can provoke severe inflammatory responses in cell cultures and animal models—confounding results in tissue repair studies—PX1 Research subjects all peptide batches to quantitative LAL endotoxin testing. Learn more about analytical methodologies in our guide on peptide purity testing via HPLC and MS.
In preclinical laboratory settings, researchers often compare CJC-1295 DAC against other GHRH derivatives and growth hormone secretagogues to evaluate receptor binding affinity, baseline clearance rates, and biological response profiles. Key comparative compounds include CJC-1295 No DAC, Sermorelin, and the ghrelin receptor agonist Ipamorelin.
While CJC-1295 DAC provides sustained GHRH receptor activation over several days via covalent albumin binding, CJC-1295 No DAC (Modified GRF 1-29) mimics the rapid, transient release of endogenous GHRH with a half-life of approximately 30 minutes. Sermorelin, representing the shortest functional sequence (1-29 amino acids), exhibits rapid clearance and is frequently used to study acute somatotrope response curves. Conversely, Ipamorelin targets the growth hormone secretagogue receptor (GHSR-1a) rather than the GHRH receptor, making it a valuable co-agent in dual-pathway secretagogue assays. Researchers exploring comparative secretagogue kinetics can consult the PX1 Research hub for technical whitepapers.
Preclinical investigations utilizing CJC-1295 DAC focus primarily on the sustained activation of the growth hormone/IGF-1 axis and its downstream downstream biological consequences. In animal models, continuous stimulation of GHRH receptors induces dose-dependent increases in baseline plasma GH concentration without abolishing physiological pulsatile GH release.
Elevated systemic growth hormone levels stimulate hepatic expression and release of IGF-1, a primary mediator of cellular growth, protein synthesis, and extracellular matrix remodeling. Preclinical studies suggest that sustained GHRH signaling enhances tissue repair mechanisms in musculoskeletal models, accelerates collagen deposition in cutaneous wound models, and promotes nitrogen retention. Investigating these pathways provides critical insights into age-related somatopause, muscle wasting mechanisms, and therapeutic target identification for regenerative medicine.
To preserve the structural integrity of CJC-1295 DAC during in vitro and in vivo assays, laboratory personnel must adhere to standardized handling protocols. Lyophilized peptide powder should be stored at -20°C or -80°C in a desiccated environment to prevent hydrolysis and moisture accumulation.
For laboratory reconstitution, researchers should utilize sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile laboratory-grade water for injection, depending on experimental design requirements:
1. Allow the lyophilized vial to reach room temperature before reconstitution to prevent condensation.
2. Gently stream the solvent down the inner glass wall of the vial rather than agitating the powder directly.
3. Swirl the vial gently until completely dissolved; do not vortex or shake vigorously, as shear forces can denature delicate peptide structures.
4. Once reconstituted, store aliquots at 2°C to 8°C for short-term experimental work (up to 30 days) or freeze at -80°C for extended stability, avoiding repeated freeze-thaw cycles. Detailed procurement options for institutional orders are available through our wholesale lab accounts portal.
CJC-1295 DAC is classified exclusively as a synthetic peptide reagent intended strictly for laboratory research use. It is not approved for human consumption, clinical diagnostic procedures, or therapeutic administration. Misrepresenting research compounds for non-laboratory applications violates standard regulatory frameworks and institutional safety guidelines.
PX1 Research is dedicated to supplying verified research materials to academic institutions, biotechnology companies, and contract research organizations (CROs). Operating out of domestic manufacturing and distribution hubs in California and Arizona, PX1 Research guarantees standard same-day shipping (Monday through Friday) for in-stock research compounds. Every lot of CJC-1295 DAC undergoes rigorous internal and independent ISO 17025 testing to ensure compliance with the highest scientific purity standards.
What does 'CJC-1295 DAC online-verkäufe' refer to in lab procurement?
It refers to international laboratory procurement channels for CJC-1295 with Drug Affinity Complex, allowing qualified research institutions to purchase high-purity GHRH analogs online for in vitro and preclinical research applications.
What is the primary mechanism of action of CJC-1295 DAC?
CJC-1295 DAC acts as a long-acting GHRH receptor agonist. The Drug Affinity Complex (DAC) permits covalent binding to circulating serum albumin, extending its biological half-life and providing sustained stimulation of growth hormone and IGF-1 secretion in animal models.
How does CJC-1295 DAC differ from CJC-1295 No DAC?
CJC-1295 DAC contains a maleimidopropionic acid moiety that binds serum albumin, extending its functional half-life to 6–8 days. CJC-1295 No DAC lacks this linker, resulting in a much shorter half-life of approximately 30 minutes, suitable for studying acute GH pulses.
How can researchers verify the purity of CJC-1295 DAC?
Laboratory researchers should review lot-specific Certificates of Analysis (COAs) featuring Reverse-Phase HPLC chromatograms (verifying ≥98% purity), Mass Spectrometry data (verifying molecular mass), and LAL assay results (verifying low endotoxin levels).
What is the correct storage temperature for lyophilized CJC-1295 DAC?
Lyophilized CJC-1295 DAC should be stored at -20°C or -80°C in a dry environment protected from light. Reconstituted solutions should be stored at 2°C to 8°C for short-term use or frozen at -80°C to prevent degradation.
Is CJC-1295 DAC approved for human use or clinical therapy?
No. CJC-1295 DAC is strictly sold as a research compound for laboratory, in vitro, and preclinical animal research applications. It is not approved for human dosing, medical treatment, or diagnostic use.
Where are PX1 Research peptides manufactured and shipped from?
PX1 Research peptides are USA-manufactured in GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona, featuring same-day shipping for orders placed Monday through Friday.
What solvent is recommended for reconstituting CJC-1295 DAC for lab assays?
Reconstitution is typically performed using sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile laboratory-grade water for injection, depending on the requirements of the specific cell culture or animal research protocol.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.